Navigation Links
BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
Date:3/23/2009

NEW HAVEN, Conn. and TORONTO, March 23 /PRNewswire/ -- BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics.

Dalton Medicinal Chemistry will apply their proprietary insights to the design and synthesis of new classes of compounds against selected Riboswitch targets. BioRelix will advance these compounds with their cutting edge array of biological assays and thorough knowledge of Riboswitch drug discovery and development.

Brian Dixon, BioRelix CEO commented, "We are pleased to have the opportunity to expand and renew our productive relationship with the creative team at Dalton Medicinal Chemistry. We are confident their expertise, insights and commitment to high quality medicinal chemistry, coupled with our propriety and leading position on Riboswitches, will continue to deliver value in important new medicines."

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to work further with BioRelix in the discovery and development of much needed new anti-infective agents. The team at BioRelix has clearly established a remarkably innovative and fundamentally groundbreaking approach to anti-infectives and we are pleased to be with them at the forefront of this medicinal chemistry and drug discovery."

About BioRelix:

BioRelix, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective product candidates based on novel patented RNA targets, termed Riboswitches, which were identified by the laboratory of BioRelix co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford
'/>"/>

SOURCE Dalton Medicinal Chemistry
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
2. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
3. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
4. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
5. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
6. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. Acesys and Provid Announce Alliance for Medicinal Chemistry Services
8. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
9. MS Drug Development Agreement Based on WEHIs Medicinal Chemistry
10. Neptune Technologies expands into medicinal markets in Asia Pacific
11. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Research and Markets has announced the addition ... Market 2014-2018" report to their offering. ... the study of the gene and its functions and ... of proteomes or sets of proteins by using molecular ... mapping of genes and DNA sequencing to understand the ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... 28 , - Guests Will ... , Staying healthy in these stressful ... Attitude Health Retreats early in 2009 may provide,participants with the ... A key component of the retreat ...
... XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , ... it received a Staff Determination Letter (the "Letter") from ... the staff of Nasdaq,s Listing Qualifications Department determined, using ... the Company,s American Depository Shares ("ADRs") would be delisted ...
... web based CTMS (Clinical Trial Management System), has ... deployed visit reports, site payments, sponsor portal and ... project will include integration to our electronic data ... as other innovative functional changes to the system ...
Cached Biology Technology:New Health Retreat Gives a Fresh Attitude Towards Disease Prevention 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 3
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... gradual extinction of cold-loving species, and the European land ... from the University of Kassel in Germany and the ... that human-induced temperature increases over a 40-year period in ... the near extinction of the local land leech Xerobdella ...
... have long known that the human body runs like clockwork, ... of light and darkness. Now a team of researchers is ... activity, which could allow them to predict optimal timing for ... solar day and relieve psychosocial stress. In short, ...
... showing that dog-walking in bushland significantly reduces bird ... against the practice in sensitive bushland and conservation ... the ecological impacts of dog-walking have remained subjective ... But the first clear evidence that birds ...
Cached Biology News:Role reversal as humans suck life out of leeches 2Researchers developing device to predict proper light exposure for human health 2Researchers developing device to predict proper light exposure for human health 3A dog in the hand scares birds in the bush 2